The discovery of a new gene could mean new approaches to treating metastasized prostate cancer.
Dr. Roseline Godbout and her team are working to uncover innovative treatment strategies for individuals diagnosed with metastasized prostate cancer (cancer that has spread to other parts of the body). While localized prostate cancer has a nearly 100 per cent survival rate, effective treatment options for metastatic prostate cancer remain limited.
As winners of the 2024 Game Changer Competition, Godbout and her team were awarded a grant of $1.25 million to explore alternative treatment options for metastatic prostate cancer.
Godbout’s research identified a gene called FABP12 that is considerably more abundant in people with metastatic prostate cancer compared to those with localized forms.
By targeting and blocking FABP12 in people with metastatic prostate cancer, it may be possible to enhance the effectiveness of existing treatment methods. This research also offers new insights into what causes prostate cancer to metastasize and presents promising strategies for preventing its spread.
Thanks to the Alberta Cancer Foundation’s donor-supported Game Changer Competition, Godbout’s research holds the potential to improve outcomes and care for people diagnosed with metastatic prostate cancer.
Thanks to the tremendous success of the We Cross Cancer campaign, the Game Changer Competition was launched in May 2023.
2024 Game Changer Winners
Dr. Roseline Godbout: New approaches to treatment for metastasized prostate cancer
Dr. Vickie Baracos: Customized treatment for cancer cachexia
Dr. Ing Swie Goping: Personalized treatment for breast cancer
Dr. Kristi Baker: Novel therapeutic treatment for late-stage cancers
